Back

Arvinas doses first participant in Phase 1/2 ARV-6723 cancer trial

Verifying
  • Arvinas dosed the first participant in its Phase 1/2 ARV-6723 trial.
  • ARV-6723 is an oral PROTAC targeting HPK1 in advanced solid tumors.
  • The trial will test monotherapy before combination treatment with pembrolizumab.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.